JAK2 and neoplasm: Alterations in cell cycle regulators are found in around 29% of the cases, affecting genes such as CDKN2A, CDKN2B and CCNE1. KIT amplification and co-amplification of tumor immune evasion genes (PD-L1, PD-L2 and JAK2) seems to be specific to ATCs, not being found in other tumor subtypes.